4D Pharma PLC (08840579): administration
- Status
- Administration ended
- Administration began
- 2022-06-24
- Administrators
- David John Pike, James Richard Clark
- Administrators' firm
- Interpath Advisory
- Formerly
- 4D Pharma Limited; Schosween 18 Limited
- Incorporated
- 2014-01-10
- Location
- Leeds
- Industry
- 72190 Other research and experimental development on natural sciences and engineering
Why it went into administration
- Funding withdrawn / unable to refinance
- Property / lease costs
- Sustained trading losses
From the administrators' statement
4D Plc and its subsidiaries are a pharmaceutical group of companies developing LBPs, a novel class of drug derived from the human gut microbiome. The Group has a diverse pipeline of development programmes in several therapeutic areas, searching to treat a number of conditions including gastro-intestinal (IBS/IBD), immuno-oncology (pancreatic cancer, lung cancer, etc.) and respiratory (asthma) diseases. The Group has launched several clinical trials, some of which are conducted in collaboration with key pharmaceutical industry players, such as MSD and Merck KGaA.
4D Plc owns intellectual property relating to 4D Group’s Phase II Blautix asset (a clinical stage drug candidate primarily aimed at treating IBS), in addition to acting as a sponsor for 4D Group’s clinical trials. Furthermore, as the listed parent company within the Group, 4D Plc was responsible for raising debt and equity funding for the Group.
As at the date of the appointment, the Company employed two members of staff, both of whom are located in France. 4D Plc operated from its leasehold head office premises in Leeds, also used by some of 4D Pharma Research’s employees.
Administrators' statement of proposals (2022-08-10) · Companies House register